A SINGLE CENTER, OPEN-LABEL, RANDOMIZED, PILOT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, ADVAGRAF®, VERSUS TACROLIMUS TWICE DAILY, PROGRAF® IN STABLE RENAL RECIPIENTS: